Glial TumorsNCT07416838
Quality of Life and Cognitive Functioning in Patients With Glial Tumors
A study testing Cognitive Functioning and Quality of Life Assessment in people with Glial Tumors, run by Institute of Oncology Ljubljana at 1 site in Slovenia.
Trial summary
The aim of this study is to introduce appropriate assessment instruments and to define patients with gliomas according to cognitive functioning and quality of life. The study will evaluate cognitive functioning as a prognostic factor for survival in patients with glial tumors and will support optimization of treatment… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Glial Tumors
- What is being tested?
- Cognitive Functioning and Quality of Life Assessment
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 1 siteSlovenia
- Study dates
- 21 Sep 2018to 31 Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult participants (≥18 years)
- Patients with histologically confirmed glial tumour
- Ability to understand the study procedures and provide written informed consent
- Ability to complete quality of life questionnaires and cognitive testing
Who cannot join
- Age <18 years
- Inability to provide informed consent
- Severe cognitive impairment or clinical condition preventing completion of questionnaires and cognitive testing
- Insufficient language proficiency to complete the questionnaires and neuropsychological testing
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Quality of Life and Cognitive Functioning as Prognostic Factor in Glial Tumours
The aim of this study is to introduce appropriate assessment instruments and to define patients with gliomas according to cognitive functioning and quality of life. The study will evaluate cognitive functioning as a prognostic factor for survival in patients with glial tumors and will support optimization of treatment strategies to improve patients' quality of life.
Read the detailed description
This prospective cohort study will assess cognitive functioning and quality of life in patients with glial tumors. The objective is to determine the prognostic value of cognitive functioning on survival, establish appropriate assessment instruments, and contribute to treatment adaptation with the goal of improving quality of life in these patients.
- Conditions
- Glial Tumors
- Being tested
- Cognitive Functioning and Quality of Life Assessment
- Keywords
- Glial Tumors
- Medical subject headings
- Glioma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cognitive Functioning and Quality of Life AssessmentOther
Assessment of cognitive functioning and quality of life in patients with glial tumors to evaluate their prognostic value and impact on survival outcomes.
| Study group | Role | What they receive |
|---|---|---|
| Glioma Patients | Other | Patients with glial tumors assessed for quality of life and cognitive functioning as prognostic factors. Receives: Other: Cognitive Functioning and Quality of Life Assessment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Quality of Life Score (EORTC QLQ-C30 and QLQ-BN20)
Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer questionnaires EORTC QLQ-C30 and the brain cancer module EORTC QLQ-BN20. Scores range from 0 to 100 points. The outcome will be reported as mean change in questionnaire score (points) from baseline to each follow-up assessment.
Measured: Baseline (before treatment); 6 weeks; 3 months; 6 months; 12 months
Secondary outcomes (1)
Change in Cognitive Function Test Performance (Neuropsychological Test Battery)
Cognitive functioning will be assessed using a neuropsychological test battery evaluating multiple cognitive domains (e.g., language, memory, executive functioning). The outcome will be reported as mean change in test scores from baseline to each follow-up assessment.
Measured: Baseline (before treatment); 6 weeks; 3 months; 6 months; 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Feb 2026
- Study start21 Sep 2018
- Primary completion31 Dec 2024
- Study completion31 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Glial TumorsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Institute of Oncology Ljubljana
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07416838
- Sponsor's protocol ID
- OI-427-GLIAL-QOL-COG
- Other IDs
- ERID-EK/158
- Status last verified
- Feb 2026
- First submitted
- 6 Feb 2026
- Last updated
- 18 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Quality of Life and Cognitive Functioning as Prognostic Factor in Glial Tumours
- ClinicalTrials.gov ID
- NCT07416838
- Acronym / sponsor ID
- OI-427-GLIAL-QOL-COG
- Conditions
- Glial Tumors
- Keywords
- Glial Tumors
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- Institute of Oncology LjubljanaUniversity, hospital or other
- Study start
- 21 Sep 2018 (actual)
- Primary completion
- 31 Dec 2024 (actual)
- Study completion
- 31 Dec 2024 (actual)
- First posted
- 18 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to introduce appropriate assessment instruments and to define patients with gliomas according to cognitive functioning and quality of life. The study will evaluate cognitive functioning as a prognostic factor for survival in patients with glial tumors and will support optimization of treatment strategies to improve patients' quality of life.
Detailed description
This prospective cohort study will assess cognitive functioning and quality of life in patients with glial tumors. The objective is to determine the prognostic value of cognitive functioning on survival, establish appropriate assessment instruments, and contribute to treatment adaptation with the goal of improving quality of life in these patients.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Glioma Patients | Other | Other: Cognitive Functioning and Quality of Life AssessmentPatients with glial tumors assessed for quality of life and cognitive functioning as prognostic factors. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adult participants (≥18 years)
- Patients with histologically confirmed glial tumour
- Ability to understand the study procedures and provide written informed consent
- Ability to complete quality of life questionnaires and cognitive testing
Key exclusion criteria (4 listed)
- Age <18 years
- Inability to provide informed consent
- Severe cognitive impairment or clinical condition preventing completion of questionnaires and cognitive testing
- Insufficient language proficiency to complete the questionnaires and neuropsychological testing
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cognitive Functioning and Quality of Life AssessmentAssessment of cognitive functioning and quality of life in patients with glial tumors to evaluate their prognostic value and impact on survival outcomes. | Other | Glioma Patients |
Primary outcome
Change in Quality of Life Score (EORTC QLQ-C30 and QLQ-BN20)
Time frame: Baseline (before treatment); 6 weeks; 3 months; 6 months; 12 months
Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer questionnaires EORTC QLQ-C30 and the brain cancer module EORTC QLQ-BN20. Scores range from 0 to 100 points. The outcome will be reported as mean change in questionnaire score (points) from baseline to each follow-up assessment.
1 secondary outcome
Change in Cognitive Function Test Performance (Neuropsychological Test Battery)
Time frame: Baseline (before treatment); 6 weeks; 3 months; 6 months; 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Glial Tumors
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Active, not recruitingPhase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Glioblastoma
RecruitingPhase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Low Grade Astrocytoma, Low Grade Glioma
RecruitingPhase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Glioblastoma
RecruitingPhase 1/2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cognitive Functioning and Quality of Life Assessment in people with Glial Tumors, run by Institute of Oncology Ljubljana at 1 site in Slovenia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Slovenia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Quality of Life Score (EORTC QLQ-C30 and QLQ-BN20) (time frame: Baseline (before treatment); 6 weeks; 3 months; 6 months; 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2026.